SRPT - Sarepta Therapeutics rated outperform by Baird on positive biomarker data

Baird has issued Sarepta Therapeutics (SRPT) an Outperform rating citing the positive topline data from the Phase 3 study conducted in partnership with Lysogene (LYSGF) for LYS-SAF302. The price target of $192 implies an 11.7% upside to today’s close.In the ongoing phase 2/3 clinical trial, the two companies evaluate LYS-SAF302 in mucopolysaccharidosis type IIIA. The changes in heparan sulfate concentration in cerebrospinal fluid are being monitored in patients for evidence of in vivo biological activity of the drug and demonstrate proof of concept.Yesterday, Lysogene reported positive biomarker data from the study noting statistically significant average reductions in the concentration of HS in the CSF of all nine patients analyzed so far, at 6 and 12 months, relative to pre-treatment values.The company said there were no statistically significant changes in serum HS concentrations proving the hypothesis that LYS-SAF302 leads to a reduction of HS entering the CSF from the brain parenchyma, with little

For further details see:

Sarepta Therapeutics rated outperform by Baird on positive biomarker data